News Releases

Mar 16, 2016
OncoMed to Present Data at the American Association of Cancer Research Annual Meeting 2016

REDWOOD CITY, Calif., March 16, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) will present new data related to its clinical and preclinical anti-cancer stem cell and immuno-oncology therapeutic candidates in a total of five presentations at the upcoming American Association of Cancer Research (AACR) Meeting to be held April 16-20, 2016 in New Orleans, LA.

Among the presentations will be multiple abstracts related to the company's novel GITRL-Fc immuno-oncology therapeutic candidate, biomarker research associated with its vantictumab (anti-FZD7, OMP-18R5) and anti-RSPO3 (OMP-131R10) clinical programs, and xenograft data for demcizumab (anti-DLL4, OMP-21M18) in non-small cell lung cancer.

The following abstracts have been selected for presentation by OncoMed scientists:

Sunday, April 17, 2016 1:00 PM — 5:00 PM

1. "Development of a RSPO3 CLIA-validated assay as a predictive biomarker for response to anti-RSPO3 antibody treatment in patients with solid tumors"
Abstract Number: 404
Presenting author: Chun Zhang, Ph.D., Associate Director, Translational Medicine
Session: Biomarkers

Monday, April 18, 2016 1:00 PM — 5:00 PM

2. "GITR ligand fusion protein (GITRL-Fc) induces T cell mediated anti-tumor immune response and can combine with anti-PDL1 to enhance anti-tumor immunity and long-term immune memory"
Abstract Number: 2214
Presenting author: Minu Srivastava, Ph.D., Senior Scientist
Session: Adoptive Cell Therapy, Immune Checkpoints and Vaccines

Tuesday, April 19, 2016 8:00 AM — 12:00 PM

3. "GITRL-Fc can significantly reduce tumor growth by stimulating innate and adaptive immunity"
Abstract number: 3215
Presenting author: Hyun-Bae Jie, Ph.D., Scientist
Session: Immune Checkpoints 2  

4. "Predictive biomarker identification for response to vantictumab (OMP-18R5; anti-Frizzled) using primary patient-derived human pancreatic tumor xenografts"
Abstract Number: 3129
Presenting author: Chun Zhang, Ph.D., Associate Director, Translational Medicine
Session: Biomarkers for Gastrointestinal, Hematologic, and Uncommon Cancers

Wednesday, April 20, 2016 8:00 AM — 12:00 PM

5. "Effects of anti-DLL4 treatment on non-small cell lung cancer (NSCLC) human xenograft tumors"
Abstract number: 4652
Presenting author: Alayne Brunner, Ph.D., Senior Scientist
Session: Cellular Responses to Anticancer Drugs

About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics.  OncoMed has seven anti-cancer therapeutic candidates in clinical development, including demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), brontictuzumab (anti-Notch1, OMP-52M51), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), ipafricept (FZD8-Fc, OMP-54F28), and anti-RSPO3 (OMP-131R10), which each target key cancer stem cell signaling pathways including Notch, Wnt and R-spondin LGR.  OncoMed is advancing its wholly owned GITRL-Fc candidate and an undisclosed immuno-oncology candidate (IO#2) toward clinical trials in the 2016-2017 timeframe.  OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). 

Additional information can be found at the company's website:

Michelle Corral
Senior Director, Investor Relations and Corporate Communications
OncoMed Pharmaceuticals
(650) 995-8373



OncoMed Pharmaceuticals, Inc. is a wholly-owned subsidiary of Mereo BioPharma Group plc.
Please visit our parent site for our Pipeline, Partnering Opportunities and Investors information.